Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-04-03
2007-04-03
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091100, C435S091500, C530S300000, C530S350000, C530S362000, C536S023100, C536S024500
Reexamination Certificate
active
10668448
ABSTRACT:
The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
REFERENCES:
patent: 4572203 (1986-02-01), Feinstein
patent: 4634586 (1987-01-01), Goodwin et al.
patent: 4718433 (1988-01-01), Feinstein
patent: 4774958 (1988-10-01), Feinstein
patent: 4844882 (1989-07-01), Widder et al.
patent: 4957656 (1990-09-01), Cerny et al.
patent: 5040537 (1991-08-01), Katakura
patent: 5107842 (1992-04-01), Levene et al.
patent: 5255683 (1993-10-01), Monaghan
patent: 5304325 (1994-04-01), Kaufman et al.
patent: 5310540 (1994-05-01), Giddey et al.
patent: 5315997 (1994-05-01), Widder et al.
patent: 5315998 (1994-05-01), Tachibana et al.
patent: 5385147 (1995-01-01), Anderson et al.
patent: 5385725 (1995-01-01), Lin et al.
patent: 5393524 (1995-02-01), Quay
patent: 5401493 (1995-03-01), Lohrmann et al.
patent: 5409688 (1995-04-01), Quay
patent: 5410516 (1995-04-01), Uhlendorf et al.
patent: 5413774 (1995-05-01), Schneider et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5445813 (1995-08-01), Schneider et al.
patent: 5512268 (1996-04-01), Grinstaff et al.
patent: 5540909 (1996-07-01), Schutt
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552133 (1996-09-01), Lambert et al.
patent: 5558853 (1996-09-01), Quay
patent: 5560364 (1996-10-01), Porter
patent: 5567415 (1996-10-01), Porter
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5849727 (1998-12-01), Porter et al.
patent: 6117858 (2000-09-01), Porter et al.
patent: 6537814 (2003-03-01), Porter et al.
patent: 0 633 030 (1985-01-01), None
patent: WO 92/05806 (1992-02-01), None
patent: WO 93/05819 (1993-04-01), None
patent: WO 94/16739 (1994-08-01), None
patent: WO 94/18954 (1994-09-01), None
patent: WO 94/28874 (1994-12-01), None
patent: WO 95/15118 (1995-06-01), None
patent: WO 95/23615 (1995-09-01), None
patent: WO 96/38180 (1996-12-01), None
patent: WO 96/38181 (1996-12-01), None
patent: WO 97/33474 (1997-09-01), None
Agrawal, S. et al, Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Branch, A. Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Chirila, T.V. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Crooke, S., Antisense Research & Application, Chapters 1-50, Ed. by S. Crooke, Publ. by Springer-Verlag, NY (1998).
Peracchi, A. Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Opalinska, J.B. et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Agrawal, S. and Kandimalla, E.R.,Molecular Medicine Today, 6:72-81 (2000).
Branch, A.,TIBS, 23:45-50, (1998).
Chirila, et al.,Biomaterials, 23:321-342, (2002).
Crooke, S., Antisense Research & Application, Chapters 1 and 2, pp. 1-50 and 50-101, Ed. By S. Crooke, Published by Springer-Verlag, New York, NY, (1998).
Peracchi, A.,Rev. Med. Virol., 14:47-64, (2004).
Anderson editorial “Gene Therapy for Genetic Diseases”, Human Gene Therapy, 5:281-282 (1994).
Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, Third Edition (1992), Applied Therapeutics, Inc., Vancouver, WA.
Bleeker, H., “On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion”, Ultrasound Med, 9:461-471 (1990).
Branch, A. Trends in Biochem. Sci., 23:45-50 (1998).
Brown, “New Media, Researchers” Oversold Gene Therapy, Advisory Panel Says, The Washington Post, p. A22 (1995).
Challita, P., “Lack of expression from a retrovial vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo”, Proc. Natl. Acad. Sci. USA, 91, 2567-2571.
Coghlan, “Gene dream fades away”, New Scientist, 148:14-15 (1995).
Gura, T, 1995, Science, vol. 270, pp. 575-577.
Jaroff, “Keys to the Kingdom”, Time, 148(14) 24-29, Fall 1996.
Kricsfeld, A., “Detection of Regional Perfusion Abnormalities During Adenoosine Stress Echocardiography Using Intravenous Perfluoropropane-enhanced Sonicated Dextrose Albumin”, J. Am. Col. of Card., special issue, Feb. 1995 (abstract).
Marshall, “Gene Therapy's Growing Pains”, Science, 269:1050-1055 (1995).
Orkin, et al., Dec. 1995, Report and Recommendations of the Panet to Assess the NIH Investment in Research on Gene Therapy.
Porter, “The mechanism and clinical implication of improved left ventricular videointensity following intravenous injection of mulit-fold dilutions of albumin with dextrose”, International J. of Card. Imag., 11:117-125 (1995).
Porter, “Transient Myocardial Contrast After Initial Exposure to Diagnostic Ultrasound Pressures With Minute Doses of Intravenously Injected Microbubbles; Demonstration and Potential Mechanisms”, Circulation, 92(9):2391-2395 (1995).
Porter, et al., “Interaction of Diagnostic Ultrasound with Synthetic Oligonucleotide-Labeled Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles”, J Ultrasound Med, 15:577-584 (1996).
Porter, T., “Echocardiograpic Detection of Residual Coronary Flow Abnormalities and Stenosis Severity After Coronary Reperfusion Using Intravenous Perfluoropropane-enhanced Sonicated Dextrose Albumin”, J. Am. Col. of Card., special issue, Feb. 1995 (abstract).
Porter, T., “Multifold Sonicated Dilutions of Albumin With Fifty Percent Dextrose Improve Left Ventricular Contrast Videointensity After Intravenous Injection in Human Beings”, J. Am. Soc. Echocard., 7(5) 465-471 (1994).
Porter, T.R., et al., “Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing High Molecular Weight, Less Soluble Gases” JACC 25(2):509-515 (1995).
Porter, T., “Myocardial Contrast Echocardiography for the Assessment of Coronary Blood Flow Reserve: Validation in Humans”, JACC, 21(2) 349-355 (1993).
Porter, T., “Noninvasive Indentification of Acute Myocardial Ischemia and Reperfusion with Contrast Ultrasound Using Intravenous Perfluoropropane-Exposed Sonicated Dextrose Albumin”, J. Am. Col. of Card., 26(1) 33-40 (1995).
Porter, T., “Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing Molecular Weight, Less Soluble Gases”, J. Am. Col. of Card., 25(2) 509-515 (1995).
Putterman, S., “Sonoluminescene: Sound into Light”, Feb. 1995, Scientific American, 46-51.
Srinivasan, Shashi Kumar “Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin”, Antisense Research and Development 5:131-139 (1995).
Xie, F., “Acute Myocardial Ischemia and Reperfusion can be Visually Identified Non-invasively with Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin Ultrasound Contrast”, Abstract From the 67th Scientific Sessions Dallas Convention Center, Dallas TX, Nov. 14-17, 1994 90(2) Part 2, Oct. 1994 (abstract).
Xie, F., “Perfluoropropane Enhanced Sonicated Dextrose Albumin Produces Visually Apparent Consistent Myocardial Opecification with Physiologic Washout and Minimal Homodynamic Changes Following . . . Injection”, Abstract From the 67th Scientific Sessions Dallas Convention Center, Dallas TX, Nov. 14-17, 1994 90(4) Part 2, Oct. 1994 (abstract).
Iversen Patrick L.
Porter Thomas R.
Board of Regents of the University of Nebraska
Freschi Gina C.
Gorthey Lee Ann
Perkins Coie LLP
Zara Jane
LandOfFree
Compositions and methods for altering the biodistribution of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for altering the biodistribution of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for altering the biodistribution of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724461